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Introduction
Ductal adenocarcinoma of the pancreas is one of the
highly aggressive tumors; the overall survival rate of less
than 6% is probably due to biological rapid development
and late tumor stage at the time of diagnosis [1].
Recently a progression model suggested that infiltrating
pancreatic cancer arises from pancreatic duct lesions that
shows to harbour activating KRAS point mutation [2].
Since 1988 KRAS is the most significant genetic
alteration in pancreatic cancer and is considered as an
early event in tumor progression [3].
In the present study we investigated a selected popula-
tion of patients who underwent pancreaticoduodenect-
omy for pancreatic adenocarcinoma, with disease free
resection margins, in order to evaluate whether a speci-
fic mutation could be related to a worst median survival
time or onset of tumor recurrence and metastatisation.
Methods
We analyzed a series of 27 patients aged more than 65
years (mean age 72, range 65 – 81), that underwent radical
pancreaticoduodenectomy at our Institution for malignant
pancreatic disease; all operations (pancreaticoduodenct-
omy following Whipple Child procedure and extended
adenectomy) have performed by the same surgeon.
The inclusion criteria were:
- radical surgical procedure with complete tumor
ablation
- resection margins without an histologically proven
tumor involvement
- adequate period of follow up (at least 12 months)
Staging has been classified following TNM classifica-
tion; grading has been assessed as well (G1), moderate
(G2) and poor (G3) differentiated.
Haematoxilin –Eosin slides have been revised by the
same pathologist in order to select the area with a per-
centage of tumor cells more than 70% and area of resec-
tion margin with normal cells.
DNA was extracted using EDTA – SDS/proteinase K
followed by phenol – chloroform and resuspended with
30 µl of DEPC treated and RNAse free water.
KRAS was analysed by means of mutant enriched PCR
(ME – PCR) to detect two hotspot in codon 12 and 13
of exon 2, that include more than 95% of mutations.
Fisher’s exact test was performed in order to evaluate
correlations between survival and clinical and pathologi-
cal findings; overall survival (OS) and disease free survi-
val (DSF) curves have been carried out using Kaplan –
Meier methods and compared with Log – Rank test.
Non – parametric t – student test and Mann Whitney
test have been used in order to compare average and
median OS between the groups analyzed.
Significant values were considered when p<0.05, with
an interval of confidence of 95%.
Results
No perioperative mortality occurred; postoperative mor-
bidity rate was 7.41%(1 case of peritoneal bleeding need-
ing re – operaton and 1 case of pancreatic fistula
treated conservatively).
20 of 27 patients (74.07%) died with a mean time of
23 months after surgery (range 12 – 51 months).
12 patients (44.44%) died for liver metastasis, in 4
cases (14.81%) local recurrence occurred; 2 patients
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(7.41%) develop both local recurrence and liver metas-
tases; brain metastases was observed in 1 case (3.70%)
and peritoneal carcinomatosis in 1 case (3.70%).
No statistical correlation was found comparing survi-
val data with gender, staging, grading and perineural
invasion.
KRAS gene was successfully amplified with enriched
PCR in all samples.
4 tumor samples (14.81%) showed a KRAS wild type,
whereas the remaining 23 (85.19%) harboured muta-
tions; in details: G12D (13 cases, 48.15%), G12R (4
cases, 14.81%), G12V (3 cases 11.11%), G12 A (1 case,
3.70%), G12C (1 case, 3.70%), G12S (1 case, 3.70%).
No mutations have been detected in codon 13.
Among the mutated patients, 4 had local recurrence
(17.39%) and no statistical correlation was found
between patients presenting the most common mutation
G12D and patients with other mutations (P=.60).
OS of G12D patients was compared with OS of
patients with other mutations by Kaplan – Meier curves
without finding statistical significance.
Similarly, we performed Kaplan – Meier curves for
testing whether disease free survival (DFS) could be sta-
tistically different between the G12 mutated group and
the other patients: no significant results were obtained.
Since all the wild type patients (WT) died during the
follow up, we compared OS of WT with those mutated
in order to evaluate if mutated patients showed a better
outcome, without finding any statistical correlation.
Despite the average OS and DFS seems to indicate a
tendency of better survival for patients that did not har-
bour G12D mutation (31.5 ± 5.6 vs 25 ± 4.5 months),
survival curves, t – student test and Mann – Whitney
test did not show statistical significance (P=0.27, P=.38
and P=.3 respectively).
Finally, the comparisons of means and medians of the
analyzed groups (G12D vs all patients; G12D vs other
mutations patients and G12D vs WT patients) did not
show statistical significance.
Conclusions
Radical resection with adequate adenectomy is the gold
standard surgical procedure and provides the only
chance to increase survival in patients with pancreatic
cancer; anyway, despite the improvement of surgical
techniques and the use of adjuvant treatments, pan-
creatic carcinoma is still one of the five leading causes
of cancer death worldwide, especially in elderly
patients [4].
Molecular investigations of pancreatic tumor deter-
mined a progression model in which KRAS gene muta-
tion is an early event in tumorigenesis, occurring in
pancreatic duct lesions with minimal cytological and
architectural atypia (PanIN 1A), and could be associated
to prognostic implications, in order to provide an useful
biomarker for pancreatic cancer [5].
Our experience demonstrated that, as reported in Lit-
erature, KRAS altered expression is very common in
pancreatic cancer, occurring in more than 85% of cases;
despite the small number of patients considered in our
study (due to a selection conducted following strict cri-
teria), we can conclude that no correlation between any
subtype of KRAS mutation, OS and DFS exist; further
investigations by enlarging patients series is needed.
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